ANDAORALCAPSULE
Approved
Jun 1997
Lifecycle
Post-LOE
Competitive Pressure
30/100
Data completeness
2/8 — Basic
PAROMOMYCIN SULFATE (paromomycin sulfate) by PharmaIN is clinical pharmacology the in-vitro and in-vivo antibacterial action of paromomycin closely parallels that of neomycin. First approved in 1997.
Drug data last refreshed 21h ago
Mechanism of Action
CLINICAL PHARMACOLOGY The in-vitro and in-vivo antibacterial action of paromomycin closely parallels that of neomycin. It is poorly absorbed after oral administration, with almost 100% of the drug recoverable in the stool.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Company
PharmaIN
WA - Bothell
Worked on PAROMOMYCIN SULFATE at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.